Latest

IPSEN

FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation for First-Line Treatment of Elderly Patients with Acute Myeloid Leukemia

2 February 2026
The Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to IPN60340 (ICT01), Ipsen’s investigational anti-BTN3A monoclonal antibody, in combination with venetoclax and azacitidine for first-line treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. This regulatory acceleration

Pneumococcal Infections Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

29 January 2026
DelveInsight’s, “Pneumococcal Infections Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal Infections pipeline landscape. It covers the Pneumococcal Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal Infections

Non-Cystic Fibrosis Bronchiectasis Market Size is projected to grow at a CAGR of 16.25% by 2034, estimates DelveInsight

29 January 2026
DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of Non-Cystic Fibrosis Bronchiectasis (NCFB), including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom),

Bioanalytical Testing Services Market Size Expected to Witness Significant Expansion at ~16% CAGR by 2032 | DelveInsight

29 January 2026
DelveInsight’s Bioanalytical Testing Services Market Insights Report 2032 provides the current and forecast market analysis, individual leading Bioanalytical Testing Services Companies market shares, challenges, Bioanalytical Testing Services Market Drivers, barriers, trends, and key market Bioanalytical Testing Services companies in the market. Get
1 39 40 41 42 43 48